---
document_datetime: 2023-09-21 20:33:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/blincyto-epar-all-authorised-presentations_en.pdf
document_name: blincyto-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3241202
conversion_datetime: 2025-12-28 04:26:25.121329
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

EU/1/15/1047/001 BLINCYTO 38.5 mcg Powder for concentrate and solution for solution for infusion Intravenous use Powder: vial (glass) Solution: vial (glass) Powder: 38.5 mcg Solution: 10 mL 1 vial + 1 vial